Logo image of TCDA

TRICIDA INC (TCDA) Stock Fundamental Analysis

NASDAQ:TCDA - Nasdaq - US89610F1012 - Common Stock - Currency: USD

0.108  -0.01 (-10%)

After market: 0.084 -0.02 (-22.22%)

Fundamental Rating

1

TCDA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TCDA have multiple concerns. TCDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCDA had negative earnings in the past year.
TCDA had a negative operating cash flow in the past year.
TCDA Yearly Net Income VS EBIT VS OCF VS FCFTCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -50M -100M -150M -200M -250M

1.2 Ratios

The profitability ratios for TCDA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCDA Yearly ROA, ROE, ROICTCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20K -40K -60K -80K

1.3 Margins

TCDA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCDA Yearly Profit, Operating, Gross MarginsTCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, TCDA has more shares outstanding
Compared to 1 year ago, TCDA has a worse debt to assets ratio.
TCDA Yearly Shares OutstandingTCDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
TCDA Yearly Total Debt VS Total AssetsTCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

TCDA has an Altman-Z score of -16.67. This is a bad value and indicates that TCDA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TCDA (-16.67) is worse than 89.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.67
ROIC/WACCN/A
WACCN/A
TCDA Yearly LT Debt VS Equity VS FCFTCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 100M -100M 200M -200M

2.3 Liquidity

TCDA has a Current Ratio of 4.87. This indicates that TCDA is financially healthy and has no problem in meeting its short term obligations.
TCDA has a Current ratio (4.87) which is in line with its industry peers.
TCDA has a Quick Ratio of 4.87. This indicates that TCDA is financially healthy and has no problem in meeting its short term obligations.
TCDA's Quick ratio of 4.87 is in line compared to the rest of the industry. TCDA outperforms 58.30% of its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 4.87
TCDA Yearly Current Assets VS Current LiabilitesTCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

TCDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.38%, which is quite impressive.
EPS 1Y (TTM)32.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TCDA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.93%
EPS Next 2Y29.27%
EPS Next 3Y20%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCDA Yearly Revenue VS EstimatesTCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
TCDA Yearly EPS VS EstimatesTCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCDA. In the last year negative earnings were reported.
Also next year TCDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCDA Price Earnings VS Forward Price EarningsTCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCDA Per share dataTCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

TCDA's earnings are expected to grow with 20.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.27%
EPS Next 3Y20%

More info and screens

0

5. Dividend

5.1 Amount

TCDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRICIDA INC

NASDAQ:TCDA (1/23/2023, 8:00:00 PM)

After market: 0.084 -0.02 (-22.22%)

0.108

-0.01 (-10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)03-27 2023-03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.62%
Ins Owner Change0%
Market Cap6.02M
Analysts45
Price Target19.72 (18159.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.69%
Min EPS beat(2)16.63%
Max EPS beat(2)20.75%
EPS beat(4)3
Avg EPS beat(4)8.46%
Min EPS beat(4)-32.64%
Max EPS beat(4)29.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.79%
EPS NY rev (1m)0%
EPS NY rev (3m)9.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.36
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.95
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0
BVpS-2.44
TBVpS-2.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.87
Quick Ratio 4.87
Altman-Z -16.67
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.38%
Cap/Depr(5y)164.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.3%
EPS Next Y38.93%
EPS Next 2Y29.27%
EPS Next 3Y20%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.21%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.22%
OCF growth 3YN/A
OCF growth 5YN/A